Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside

Timofei S Zatsepin,1–3 Yuri V Kotelevtsev,1 Victor Koteliansky1,2 1Center of Functional Genomics, Skolkovo Institute of Science and Technology, 2Department of Chemistry, Lomonosov Moscow State University, 3Production Department, Central Research Institute of Epidemiology, Moscow, Russia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zatsepin TS, Kotelevtsev YV, Koteliansky V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	RNA therapeutics siRNA mRNA lipid nanoparticle targeted delivery clinical trial Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/de001ee4390b43549ac852fcfb30b525
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de001ee4390b43549ac852fcfb30b525
record_format	dspace
spelling	oai:doaj.org-article:de001ee4390b43549ac852fcfb30b5252021-12-02T07:22:59ZLipid nanoparticles for targeted siRNA delivery – going from bench to bedside1178-2013https://doaj.org/article/de001ee4390b43549ac852fcfb30b5252016-07-01T00:00:00Zhttps://www.dovepress.com/lipid-nanoparticles-for-targeted-sirna-delivery-ndash-going-from-bench-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Timofei S Zatsepin,1–3 Yuri V Kotelevtsev,1 Victor Koteliansky1,2 1Center of Functional Genomics, Skolkovo Institute of Science and Technology, 2Department of Chemistry, Lomonosov Moscow State University, 3Production Department, Central Research Institute of Epidemiology, Moscow, Russia Abstract: This review covers the basic aspects of small interfering RNA delivery by lipid nanoparticles (LNPs) and elaborates on the current status of clinical trials for these systems. We briefly describe the roles of all LNP components and possible strategies for their improvement. We also focus on the current clinical trials using LNP-formulated RNA and the possible outcomes for therapy in the near future. Also, we present a critical analysis of selected clinical trials that reveals the common logic behind target selection. We address this review to a wide audience, especially to medical doctors who are interested in the application of RNA interference–based treatment platforms. We anticipate that this review may spark interest in this particular audience and generate new ideas in target selection for the disorders they are dealing with. Keywords: RNA therapeutics, siRNA, mRNA, lipid nanoparticle, targeted delivery, clinical trialZatsepin TSKotelevtsev YVKoteliansky VDove Medical PressarticleRNA therapeuticssiRNAmRNAlipid nanoparticletargeted deliveryclinical trialMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss default, Pp 3077-3086 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	RNA therapeutics siRNA mRNA lipid nanoparticle targeted delivery clinical trial Medicine (General) R5-920
spellingShingle	RNA therapeutics siRNA mRNA lipid nanoparticle targeted delivery clinical trial Medicine (General) R5-920 Zatsepin TS Kotelevtsev YV Koteliansky V Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside
description	Timofei S Zatsepin,1–3 Yuri V Kotelevtsev,1 Victor Koteliansky1,2 1Center of Functional Genomics, Skolkovo Institute of Science and Technology, 2Department of Chemistry, Lomonosov Moscow State University, 3Production Department, Central Research Institute of Epidemiology, Moscow, Russia Abstract: This review covers the basic aspects of small interfering RNA delivery by lipid nanoparticles (LNPs) and elaborates on the current status of clinical trials for these systems. We briefly describe the roles of all LNP components and possible strategies for their improvement. We also focus on the current clinical trials using LNP-formulated RNA and the possible outcomes for therapy in the near future. Also, we present a critical analysis of selected clinical trials that reveals the common logic behind target selection. We address this review to a wide audience, especially to medical doctors who are interested in the application of RNA interference–based treatment platforms. We anticipate that this review may spark interest in this particular audience and generate new ideas in target selection for the disorders they are dealing with. Keywords: RNA therapeutics, siRNA, mRNA, lipid nanoparticle, targeted delivery, clinical trial
format	article
author	Zatsepin TS Kotelevtsev YV Koteliansky V
author_facet	Zatsepin TS Kotelevtsev YV Koteliansky V
author_sort	Zatsepin TS
title	Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside
title_short	Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside
title_full	Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside
title_fullStr	Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside
title_full_unstemmed	Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside
title_sort	lipid nanoparticles for targeted sirna delivery – going from bench to bedside
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/de001ee4390b43549ac852fcfb30b525
work_keys_str_mv	AT zatsepints lipidnanoparticlesfortargetedsirnadeliveryndashgoingfrombenchtobedside AT kotelevtsevyv lipidnanoparticlesfortargetedsirnadeliveryndashgoingfrombenchtobedside AT kotelianskyv lipidnanoparticlesfortargetedsirnadeliveryndashgoingfrombenchtobedside
_version_	1718399485729570816

Lipid nanoparticles for targeted siRNA delivery &ndash; going from bench to bedside

Ejemplares similares

Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside